# Nevro Corp

its HFX iQ spinal cord stimulation system, which integrates AI-driven personalization (HFX AdaptivAI) with its 10 kHz therapy, received CE Mark certification in Europe in November 2024 and holds an FDA-specific indication for non-surgical back pain, based on the SENZA-NSRBP randomized controlled trial.

Source: https://en.bioecon.ru/companies/nevro-corp/
Updated: 2026-07-20

- Country: United States
- Ticker: NVRO

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Certification | CE Mark certification for HFX iQ spinal cord stimulation system in Europe (2024-11-12) | https://intl.nevro.com/English/us/investors/investor-news/investor-news-details/2024/Nevros-HFX-iQ-Spinal-Cord-Stimulation-with-AI-Technology-Receives-CE-Mark-Certification-in-Europe-Increasing-Product-Expansion-Globally/default.aspx, https://www.massdevice.com/nevro-ce-mark-spinal-cord-stim-q3-2024/, https://www.prnewswire.com/news-releases/nevros-hfx-iq-spinal-cord-stimulation-with-ai-technology-receives-ce-mark-certification-in-europe-increasing-product-expansion-globally-302301647.html |
| Regulatory approval | FDA approval for HFX iQ system in the United States (2022-01-01) | https://intl.nevro.com/English/us/investors/investor-news/investor-news-details/2024/Nevros-HFX-iQ-Spinal-Cord-Stimulation-with-AI-Technology-Receives-CE-Mark-Certification-in-Europe-Increasing-Product-Expansion-Globally/default.aspx, https://www.prnewswire.com/news-releases/nevro-announces-the-launch-of-hfx-adaptivai-the-only-ai-driven-technology-in-spinal-cord-stimulation-302256481.html, https://www.prnewswire.com/news-releases/nevros-hfx-iq-spinal-cord-stimulation-with-ai-technology-receives-ce-mark-certification-in-europe-increasing-product-expansion-globally-302301647.html, https://www.sec.gov/Archives/edgar/data/1444380/000095017024127066/nvro-ex99_1.htm |
| Regulatory approval | FDA approval for HFX AdaptivAI in the United States (2024-09-24) | https://trial.medpath.com/news/nevro-wins-fda-nod-for-ai-driven-spinal-cord-stimulation-tech-massdevice, https://www.prnewswire.com/news-releases/nevro-announces-the-launch-of-hfx-adaptivai-the-only-ai-driven-technology-in-spinal-cord-stimulation-302256481.html, https://www.prnewswire.com/news-releases/nevros-hfx-iq-spinal-cord-stimulation-with-ai-technology-receives-ce-mark-certification-in-europe-increasing-product-expansion-globally-302301647.html, https://www.sec.gov/Archives/edgar/data/1444380/000095017024127066/nvro-ex99_1.htm |
| Revenue | $408.5 million for full-year 2024 worldwide revenue (2024-12-31) | https://last10k.com/sec-filings/nvro/0001444380-25-000021.htm |
| Production site | Manufacturing facility in Costa Rica | https://www.prnewswire.com/news-releases/nevro-initiates-plan-for-manufacturing-operations-in-costa-rica-to-support-future-growth-301129871.html, https://www.sec.gov/Archives/edgar/data/1444380/000095017024019464/nvro-20231231.htm |

Independent sources: intl.nevro.com, last10k.com, massdevice.com, prnewswire.com, sec.gov, trial.medpath.com

## Technologies

- [Bioelectronic medicine & neuromodulation](https://en.bioecon.ru/technology/bioelectronic-medicine-neuromodulation/)